TRVI
Trevi Therapeutics, Inc. · Healthcare
Insiders sold $596K of Trevi Therapeutics, Inc. in the last 12 months and bought none
TRVI over the last year
TRVI after insider buys
3 months after each buy, from the first price a copier could get.
1 buy has 3 months of prices so far. A record shows here at 3.
Every filing
41 insider filings since 2019, newest first
Michael Thomas Heffernan · Director
Jennifer L Good · President and CEO
Thomas Sciascia · Chief Scientific Officer
Thomas Sciascia · Chief Scientific Officer
Thomas Sciascia · Chief Scientific Officer
Jennifer L Good · President and CEO
Tpg Gp A, LLC · Former 10% Owner
Tpg Gp A, LLC · 10% owner
Tpg Gp A, LLC · 10% owner
Ali Behbahani · 10% owner
New Enterprise Associates 16, L.P. · 10% owner
Paul Edward Walker · 10% owner
Peter W. Sonsini · 10% owner
Scott D Sandell · 10% owner
Mohamad Makhzoumi · 10% owner
Anthony A. Florence Jr. · 10% owner
Carmen Chang · 10% owner
Forest Baskett · 10% owner
Ali Behbahani · 10% owner
New Enterprise Associates 16, L.P. · 10% owner
Tpg Group Holdings (Sbs) Advisors, Inc. · 10% owner
Paul Edward Walker · 10% owner
Peter W. Sonsini · 10% owner
Scott D Sandell · 10% owner
David M Mott · 10% owner
Joshua Makower · 10% owner
Mohamad Makhzoumi · 10% owner
Anthony A. Florence Jr. · 10% owner
Carmen Chang · 10% owner
Forest Baskett · 10% owner
Peter J Barris · 10% owner
David P Meeker · Director and 10% owner
Omega Fund V, L.P. · 10% owner
Mellon Family Investment Co V · 10% owner
Michael Thomas Heffernan · Director
Jennifer L Good · 10% owner
Aperture Venture Partners Iv, L.P. · 10% owner
Mette Kirstine Agger · Director
Richard King Mellon Foundation · 10% owner
Anne Vanlent · Director
Invest A/s Lundbeckfond · 10% owner
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.